News Oragenics, Inc.

Equities

Market Closed - Nyse Other stock markets 01:40:00 30/04/2024 am IST			5-day change	1st Jan Change
1.01 ^USD	-1.94%		-4.72%	-82.05%

12/04	North American Morning Briefing : Big Banks Kick -2-	DJ
29/03	Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards	20/04	BU
North American Morning Briefing : Big Banks Kick -2-	12/04	DJ
Oragenics, Inc. Files 10K and Provides Company Update	01/04	BU
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18/03	BU
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	18/03	CI
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05/03	BU
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	05/03	CI
Oragenics Announces Closing of Public Offering	04/03	AQ
Oragenics Announces Closing of Public Offering	02/03	BU
Top Midday Decliners	29/02	MT
Oragenics Announces Pricing of Public Offering	28/02	BU
Oragenics Announces Proposed Public Offering	28/02	BU
Oragenics CEO Kimberly Murphy Steps Down, Board Chair to Serve as Interim Executive Chair	13/02	MT
Oragenics, Inc. Announces Leadership Transition	13/02	BU
Oragenics, Inc. Announces Leadership Transition	13/02	CI
Oragenics, Inc. Announces CEO Changes	13/02	CI
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement	07/02	BU
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion	05/02	BU
Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion	05/02	CI

No results for this search